Sanofi’s Post

View organization page for Sanofi, graphic

4,091,267 followers

Today, phase 3 data published in The New England Journal of Medicine (NEJM) set the stage for the future of care for children under 12 with severe #hemophilia A. Learn more about what these results mean for this population. Read our press release: http://spkl.io/60464CTmO NEJM Group

  • No alternative text description for this image
Alaa Hamed, MD, MPH, MBA

Global Head of Medical Affairs Rare Diseases

1mo

This is important news for children with #hemophilia A and their caregivers. When we focus our efforts holistically on the outcomes that are most important to people affected by the condition, we have the potential to meaningfully transform care. Congratulations to the authors and the Sanofi Medical and Clinical teams for this milestone, and thank you to the participants who made this study possible. Alicia Mack, PharmD, Jennifer Dumont, Annemieke Willemze, Cecile Le Camus

Kudos to the dedicated researchers and medical professionals driving innovation in pediatric care. 

As fas as i understand, there are no severe site effects observed fo far an it is harmless to children at 6 years of age. The painful bleeding into joits is reduced by more than 95% by one injection weeklly. Great work I love the recent emphasis on rare diseases.

Like
Reply

These are such informative insights. 🙌

Like
Reply

Incredible work 🙏🏼

Like
Reply
Elvira Ponce León

Senior Director Global Medical Affairs Rare Diseases at Sanofi-Genzyme

1mo

Love this 😍

Like
Reply

It's a great news that Sanofi and Sobi help the children suffered from hemophilia A.

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics